Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection.
Replication-defective mutants of herpes simplex virus type 1 (HSV-1) were used as a new means to immunize mice against HSV-1-mediated ocular infection and disease. The effects of the induced immune responses on pathogenesis of acute and latent infection by challenge virus were investigated after corneal inoculation of immunized mice with virulent HSV-1. A single subcutaneous injection of replication-defective mutant virus protected mice against development of encephalitis and keratitis. Replication of the challenge virus at the initial site of infection was lower in mice immunized with attenuated, wild-type parental virus (KOS1.1) or replication-defective mutant virus than in mice immunized with uninfected cell extract or UV-inactivated wild-type virus. Significantly, latent infection in the trigeminal ganglia was reduced in mice given one immunization with replication-defective mutant virus and was completely prevented by two immunizations. Acute replication in the trigeminal ganglia was also prevented in mice immunized twice with wild-type or mutant virus. The level of protection against infection and disease generated by immunization with replication-defective mutant viruses was comparable to that of infectious wild-type virus in all cases. In addition, T-cell proliferative and neutralizing antibody responses following immunization and corneal challenge were of similar strength in mice immunized with replication-defective mutant viruses or with wild-type virus. Thus, protein expression by forms of HSV-1 capable of only partially completing the replication cycle can induce an immune response in mice that efficiently decreases primary replication of virulent challenge virus, interferes with acute and latent infection of the nervous system, and inhibits the development of both keratitis and systemic neurologic disease.
Morrison
L A
LA
Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115.
Knipe
D M
DM
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004268:DNA-Binding Proteins; D003673:Defective Viruses / Q000276:immunology*; D005123:Eye / Q000382:microbiology; D005260:Female; D006561:Herpes Simplex / Q000517:prevention & control*; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000254:growth & development / Q000276:immunology*; D017874:Immediate-Early Proteins; D007111:Immunity, Cellular; D007114:Immunization; D007274:Injections, Intraperitoneal; D016849:Keratitis, Herpetic / Q000209:etiology / Q000517:prevention & control; D051379:Mice; D008807:Mice, Inbred BALB C; D016296:Mutagenesis; D009422:Nervous System Diseases / Q000517:prevention & control; D012668:Trigeminal Ganglion / Q000382:microbiology; D014764:Viral Proteins / Q000235:genetics; D017735:Virus Latency; D014779:Virus Replication
D000914:Antibodies, Viral; D004268:DNA-Binding Proteins; C057120:ICP27 protein, human herpesvirus 1; C045462:ICP8 protein, Simplexvirus; D017874:Immediate-Early Proteins; D014764:Viral Proteins